Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third Party CMVpp65-specific T-cells for CMV after HCT
NCT02136797Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2014
- Primary completion
- Feb 2024
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CMVpp65-specific T-cells in cytomegalovirus infection (CMV) and cytomegalovirus infection, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Complete Response at 2 years. Started May 2014; status: completed.
02
Drugs
CMVpp65-specific T-cells
03
Conditions
cytomegalovirus infection (CMV)cytomegalovirus infection
Beyond the preview
Go deeper on NCT02136797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02136797.